Former executives at Valeant and Philidor found guilty in multimillion-dollar kickback scheme  

A former Valeant executive and a former executive of its mail order division Philidor were found guilty of defrauding the drugmaker out of millions of dollars. (Valeant)

A jury in New York on Tuesday found a former executive of mail order pharmacy Philidor Rx Services and a former Valeant Pharmaceuticals executive guilty of defrauding the drugmaker in a multimillion-dollar scheme, for once putting the New Jersey drug company in the unusual role of a victim of dirty dealings.

Gary Tanner, a former senior director at Valeant, and Andrew Davenport, the former head of the now-defunct Philidor, were convicted of fraud and conspiracy, Reuters reported.

Attorneys for the men told Reuters they would appeal.


Bioavailability Enhancement – Industry Insights, Key Challenges & Advanced Development Solutions

Join this webcast on Tuesday, June 16 as experts present the exclusive survey findings and introduce innovative scalable drug delivery technologies proven to address the industry’s growing need for improving solubility and enhancing bioavailability.

Valeant has often found itself defending its sales and pricing tactics to investigators and congressmen. In fact, the once-high-flying Valeant ran into scrutiny in the fall of 2015 after short seller Citron Research detailed the drugmaker's relationship to Philidor. But during the two-week-long trial, federal prosecutors painted Valeant as the victim of a fraud.

RELATED: Feds hit former Valeant, Philidor execs with multimillion-dollar fraud and kickback charges

They presented evidence showing that Valent’s Tanner passed inside information to Davenport to inflate Philidor’s business as the drugmaker's primary pharmacy partner. For his role, Davenport kicked back $9.7 million to Tanner when Valeant decided to buy Philidor. Davenport reaped $40 million for himself.

Philidor is now shut down and Valeant is working to move past its problems. Part of that effort involves changing its name in July to Bausch Health Companies, leaning on the goodwill of its Bausch & Lomb contact opticals business.

Suggested Articles

Not wanting to be left behind in the COVID-19 vaccine race, Europe is stepping up its efforts secure supplies if any immunizations prove effective.

The Trump administration has selected five COVID-19 vaccines for Operation Warp Speed, the NYT reports, with Big Pharma dominating the list.

Racing with some COVID-19 vaccine heavyweights, Novavax has brought on a partner to manufacture adjuvant for its in-development shot.